IP Verse

Anticancer Compositions - EP3226843

The patent EP3226843 was granted to Aragon Pharmaceuticals on May 26, 2021. The application was originally filed on Dec 3, 2015 under application number EP15820351A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3226843

ARAGON PHARMACEUTICALS
Application Number
EP15820351A
Filing Date
Dec 3, 2015
Status
Opposition Rejected
Mar 21, 2025
Grant Date
May 26, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSFeb 25, 2022D YOUNGADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2013184681
INTERNATIONAL-SEARCH-REPORTWO2013152342
INTERNATIONAL-SEARCH-REPORTWO2015118015
OPPOSITIONWO02080902
OPPOSITIONWO03063821
OPPOSITIONWO2013152342
OPPOSITIONWO2013184681
OPPOSITIONWO2014043208
OPPOSITIONWO2014113260

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- AL-OBAIDI H et al., "Evaluation of Griseofulvin Binary and Ternary Solid Dispersions with HPMCAS", AAPS PharmSciTech, (20091200), vol. 10, no. 4, pages 1172 - 1177, XP055905662-
OPPOSITION- Anonymous, "Abbott Receives US FDA Approval for Hear-Stable Norvir@ (ritonavir) Tablets", Press Release, (20100211), pages 1 - 10, XP055905823-
OPPOSITION- Anonymous, "CHMP Assessment Report For Intelence - International Nonproprietary Name: etravirine Procedure No. EMEA/H/C/000900", EMEA, (20080000), pages 1 - 52, XP055905702-
OPPOSITION- Anonymous, "European Medicines Agency EMA/200986/2012", Assessment Report, (20111200), pages 1 - 13, XP055905829-
OPPOSITION- Anonymous, "History of Changes for Study: NCT02123758 A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer", NCT02123758, (20141202), pages 1 - 12, XP055850235-
OPPOSITION- Anonymous, "History of changes for study : NCT02160756 Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants", NCT02160756, (20141113), pages 1 - 5, XP055905635-
OPPOSITION- Anonymous, "Incivo (telaprivir) EMA Assessment Report", European Medicines Agency, (20110700), pages 1 - 16, XP055905833-
OPPOSITION- Anonymous, "Kalydeco (ivacaftor) EMA Assessment Report", European Medicines Agency, (20110700), pages 1 - 13, XP055905838-
OPPOSITION- Anonymous, "New Kaletra Tablets FDA Approved: Abbott Press Release", HIV Articles, (20051031), pages 1 - 3, XP055905753-
OPPOSITION- Anonymous, "New Kaletra Tablets FDA Approved: Abbott Press Release", HIV Articles, (20060907), pages 1 - 3, XP055905753-
OPPOSITION- CHMP, "Everolimus EMA Assessment Report - Procedure No.:EMEA/H/C002311/0000", European Medicines Agency, (20110623), pages 1 - 104, XP055905721-
OPPOSITION- KUMAR P et al., "A Study on solubility enhancement methods for poorly water soluble drugs", American Journal of Pharmacological Sciences, (20130000), vol. 1, no. 4, pages 67 - 73, XP055850216-
OPPOSITION- WUETS et al., "Physicochemical Properties of the Amorphous Drug, Cast Films, and Spray Dried Powders to Predict Formulation Probability Of Success for Solid Dispersions: Etravirine", J Pharm Sci Jan, (20110000), vol. 100, no. 1, pages 260 - 274, XP055850244-
OPPOSITION- William Curatolo; James A Nightingale; Scott M Herbig, "Utility of Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and Maintenance of Drug Supersaturation in the GI Milieu", Pharmaceutical Research, (20090600), vol. 26, no. 6, pages 1419 - 1431, XP019686188
OPPOSITION- Yanbin Huang; Wei-Guo Dai, "Fundamental aspects of solid dispersion technology for poorly soluble drugs", Acta Pharmaceutica Sinica B, (20140200), vol. 4, no. 1, pages 18 - 25, XP055497465
OPPOSITION- Dwayne T Friesen; Ravi Shanker; Marshall Crew; Daniel T Smithey; Curatolo W J; Nightingale J A S, "Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview", Mol Pharm, (20080000), vol. 5, no. 6, pages 1003 - 1019, XP055056966
OPPOSITION- Williams H D; Trevaskis N L; Charman S A; Shanker R M; Charman W N; Pouton C W; Porter C J H, "Strategies to Address Low Drug Solubility in Discovery and Development", Pharmacol Rev, (20130100), vol. 65, no. 1, pages 315 - 499, XP055157770
OPPOSITION- Srinarong Parinda; De Waard Hans; Frijlink H, "Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations", Srinarong Expert Opin. Drug Deliv., (20110000), vol. 8, no. 9, pages 1121 - 1140, XP055839893

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents